Back Back
Cell No. : Cell Name
RCB0440 : LC-2/ad  update : 2022/01/11
CommentAdenocarcinoma, moderately differentiated. Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Itoh, Hiroshi
Originator Kataoka, Hiroaki
Year of deposit 1989
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 51 years
Tissue lung, pleural fluid
Disease name adenocarcinoma
Classification cancer
Year of origin 1986
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_1373
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives (HamF12 : RPMI1640 = 1 : 1) + 25mM HEPES + 15% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2-3 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP, MPI, PepB
Chromosome mode 99-206(50) : /101(4),102(2),103(11),104(14),105(7)/
STR(human) OK
deposit info
lot info
Reference information Reference 1
User's Publication 50

To topTop
1780  Kataoka H, Itoh H, Seguchi K, Koono M  Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing α1-anititrypsin In Vitro  Acta Pathologica Japonica  1993  43:566-573  PubMed ID: 8291444

To topTop
User's Publication
13332  Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K.  Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer.  Oncol Rep  2021    PubMed ID: 33155667
20104  Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y.  Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer.  Cancer Med  2021    PubMed ID: 33826244
20304  Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K.  Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.  Lung Cancer  2021  158:115-125  PubMed ID: 34157583
12021  Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M, Tsukahara T, Suzuki T.  The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB.  Biochem. Biophys. Res. Commun.  2020    PubMed ID: 31982139
12063  Kuchitsu Y, Nagashio R, Igawa S, Kusuhara S, Tsuchiya B, Ichinoe M, Satoh Y, Naoki K, Murakumo Y, Saegusa M, Sato Y.  TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma.  Biomed. Res.  2020    PubMed ID: 32092740
13900  Fujimura T, Furugaki K, Harada N, Yoshimura Y.  Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells  Cancer Biol Ther  2020  21(9):863-870  PubMed ID: 32835580
14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677
11833  Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, Kusuhara S, Igawa S, Shiomi K, Goshima N, Murakumo Y, Saegusa M, Satoh Y, Masuda N, Naoki K.  Prognostic significance of IMMT expression in surgically-resected lung adenocarcinoma.  Thorac Cancer  2019    PubMed ID: 31583841
11040  Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura   Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion  BMC Cancer  2019  19(1):301  PubMed ID: 30943926
12502  Hagiuda D, Nagashio R, Ichinoe M, Tsuchiya B, Igawa S, Naoki K, Satoh Y, Murakumo Y, Saegusa M, Sato Y.  Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma  Biomed Res  2019  40(1):17-27  PubMed ID: 30787260
11149  Shimizu K, Okita R, Saisho S, Maeda AI, Nojima Y, Nakata M.  Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.  Anticancer Res.  2018  38(8):4637-4644  PubMed ID: 30061230
11223  Terashima M, Ishimura A, Wanna-Udom S, Suzuki T.  MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells.  J. Biol. Chem.  2018    PubMed ID: 30262664
4183  Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.  Oncoimmunology  2018    PubMed ID: 30510853
9949  Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS.  EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.  Yonsei Med. J.  2017  58:9-18  PubMed ID: 27873490
9950  Terashima M, Tange S, Ishimura A, Suzuki T.  MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.  J. Biol. Chem.  2017  292:82-99  PubMed ID: 27852821
10280  Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A.  AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.  Oncol. Rep.  2017  37:3261-3269  PubMed ID: 28440492
10408  Terashima M, Ishimura A, Wanna-Udom S, Suzuki T.  Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.  Biochem. Biophys. Res. Commun.  2017  490:1407-1413  PubMed ID: 28698146
10464  Reeser JW, Martin D, Miya J, Kautto EA, Lyon E, Zhu E, Wing MR, Smith A, Reeder M, Samorodnitsky E, Parks H, Naik KR, Gozgit J, Nowacki N, Davies KD, Varella-Garcia M, Yu L, Freud AG, Coleman J, Aisner DL, Roychowdhury S.  Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.  J Mol Diagn  2017  19:682-696  PubMed ID: 28802831
10922  Shigeaki Umeda et al  Loss of IL-24 expression facilitates invasion in lung adenocarcinoma   Int J Clin Exp Pathol  2017  10:173-185 
14222  Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T.  Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC  Mol Cancer Res  2017  15(10):1354-1365  PubMed ID: 28698358
14232  Yasunaga M, Manabe S, Matsumura Y.  Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease  Sci Rep  2017  7(1):10735  PubMed ID: 28878234
14355  Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M.  PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer  Cancer Immunol Immunother   2017  66(7):865-876  PubMed ID: 28341875
9522  Nishijima N, Seike M, Soeno C, Chiba M, Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K, Gemma A.  miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.  Int. J. Oncol.  2016  48:937-44  PubMed ID: 26783187
12967  Okita R, Yukawa T, Nojima Y, Maeda A, Saisho S, Shimizu K, Nakata M.  MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer  Cancer Immunol Immunother  2016  65(5):499-509.  PubMed ID: 26940474
13983  Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y.  Loss of YAP1 defines neuroendocrine differentiation of lung tumors  Cancer Sci  2016  107(10):1527-1538  PubMed ID: 27418196
15849  Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.  Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients  Clin Cancer Res  2016  22(4):915-22  PubMed ID: 26459174
7452  Liu G, Wu Q, Liu G, Song X, Zhang J.  Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans.  Cancer Cell Int.  2015  15:18  PubMed ID: 25745359
13810  Chen S, Huang L, Sun K, Wu D, Li M, Li M, Zhong B, Chen M, Zhang S.  Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis  PLoS One  2015  10(5):e0125480  PubMed ID: 25974088
14286  Katono K, Sato Y, Jiang SX, Kobayashi M, Nagashio R, Ryuge S, Fukuda E, Goshima N, Satoh Y, Saegusa M, Masuda N.  Prognostic significance of MYH9 expression in resected non-small cell lung cancer  PLoS One  2015  10(3):e0121460  PubMed ID: 25826333
14314  Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M.  Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells  PLoS One  2015  10(10):e0139809  PubMed ID: 26439264
15025  Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y.  Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment  Genome Biol  2015  16(1):66  PubMed ID: 25887790
15117  Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, Kubota K, Gemma A.  Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer  Mol Cancer Ther  2015  14(11):2433-40  PubMed ID: 26351321
15123  Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, Paik S, Kim DJ, Kim JH, Cho BC.  Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma  Mol Cancer Ther  2015  14(10):2238-48  PubMed ID: 26208525
15182  Saito K, Kobayashi M, Nagashio R, Ryuge S, Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, Masuda N, Sato Y.  S100A16 is a Prognostic Marker for Lung Adenocarcinomas  Asian Pac J Cancer Prev  2015  16(16):7039-44  PubMed ID: 26514487
15456  Yanagita K, Nagashio R, Ryuge S, Katono K, Jiang SX, Tsuchiya B, Nakashima H, Fukuda E, Goshima N, Saegusa M, Satoh Y, Masuda N, Sato Y.  Serum Anti-Gal-3 Autoantibody is a Predictive Marker of the Efficacy of Platinum-Based Chemotherapy against Pulmonary Adenocarcinoma  Asian Pac J Cancer Prev  2015  16(17):7959-65  PubMed ID: 26625826
4866  Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.  Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.  Mol Cancer Ther  2014  13(12):2910-8  PubMed ID: 25349307
15845  Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A.  MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells  Mol Cancer Ther  2014  13(2):444-53  PubMed ID: 24258346
7714  Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, Hagiwara K, Koyama N.  Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.  Cancer  2012  118:1599-606  PubMed ID: 21837672
14287  Kobayashi M, Matsumoto T, Ryuge S, Yanagita K, Nagashio R, Kawakami Y, Goshima N, Jiang SX, Saegusa M, Iyoda A, Satoh Y, Masuda N, Sato Y.  CAXII Is a sero-diagnostic marker for lung cancer  PLoS One  2012  7(3):e33952  PubMed ID: 22439015
15847  Mizutani H, Okano T, Minegishi Y, Matsuda K, Sudoh J, Kitamura K, Noro R, Soeno C, Yoshimura A, Seike M, Gemma A.  HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner  Oncol Lett  2010  1(6):1011-1016  PubMed ID: 22870103
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309
2481  Okudela K, Yazawa T, Woo T, Sakaeda M, Ishii J, Mitsui H, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Takahashi T, Sugimura H, Kitamura H.  Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.  Am J Pathol  2009  175(2):867-81  PubMed ID: 19608870
12769  Okudela K, Yazawa T, Ishii J, Woo T, Mitsui H, Bunai T, Sakaeda M, Shimoyamada H, Sato H, Tajiri M, Ogawa N, Masuda M, Sugimura H, Kitamura H.  Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis  Am J Pathol  2009  175(6):2646-56  PubMed ID: 19893046
3580  Ito T, Maki N, Hazeki O, Sasaki K, Nekooki M.  Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines.  Cell Biol Int  2007  31(12):1518-24  PubMed ID: 17719804
3061  Nagai, Yoshiaki, Miyazawa, Hitoshi, Tanaka, Tomoaki, Udagawa, Kiyoshi, Kato, Motoyasu, Fukuyama, Shunichiro, Yokote, Akemi, Kobayashi, Kunihiko, Kanazawa, Minoru, Hagiwara, Koichi, Hagiwara K  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.  Cancer Res  2005  65:7276-82  PubMed ID: 16105816
13698  Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, Nishimura Y, Funata N, Fukayama M.  Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes  Cancer Sci  2005  96(12):844-57  PubMed ID: 16367903
3338  Seike, Masahiro, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Gemma, Akihiko, Kudoh, Shoji, Hirohashi, Setsuo  Proteomic signature of human cancer cells.  Proteomics  2004  4:2776-88  PubMed ID: 15352251
13743  Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, Maeshima A, Yamada T, Matsuno Y, Fukayama M, Yokota J, Hirohashi S.  Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas  Am J Pathol  2002  160(3):1129-41  PubMed ID: 11891209
6175  Arai K, Teratani T, Nozawa R, Yamada T.  Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation.  Oncol Rep  2001  8(3):591-6  PubMed ID: 11295086
2483  Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.  Clin Cancer Res  2000  6:2431-9  PubMed ID: 10873096

Back Back Return Top Page